HRP20120066T1 - Kalijeva sol inhibitora hiv integraze - Google Patents

Kalijeva sol inhibitora hiv integraze Download PDF

Info

Publication number
HRP20120066T1
HRP20120066T1 HR20120066T HRP20120066T HRP20120066T1 HR P20120066 T1 HRP20120066 T1 HR P20120066T1 HR 20120066 T HR20120066 T HR 20120066T HR P20120066 T HRP20120066 T HR P20120066T HR P20120066 T1 HRP20120066 T1 HR P20120066T1
Authority
HR
Croatia
Prior art keywords
compound
treatment
prophylaxis
monopotassium salt
salt
Prior art date
Application number
HR20120066T
Other languages
English (en)
Croatian (hr)
Inventor
M. Belyk Kevin
G. Morrison Henry
Jones Philip
Summa Vincenzo
Original Assignee
Merck Sharp & Dohme Corp.
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36171569&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20120066(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme Corp., Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. filed Critical Merck Sharp & Dohme Corp.
Publication of HRP20120066T1 publication Critical patent/HRP20120066T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D313/12—[b,e]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HR20120066T 2004-12-03 2005-12-02 Kalijeva sol inhibitora hiv integraze HRP20120066T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63313204P 2004-12-03 2004-12-03
PCT/US2005/043728 WO2006060712A2 (en) 2004-12-03 2005-12-02 Potassium salt of an hiv integrase inhibitor

Publications (1)

Publication Number Publication Date
HRP20120066T1 true HRP20120066T1 (hr) 2012-03-31

Family

ID=36171569

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20120066T HRP20120066T1 (hr) 2004-12-03 2005-12-02 Kalijeva sol inhibitora hiv integraze

Country Status (35)

Country Link
US (2) US7754731B2 (OSRAM)
EP (2) EP1819683B1 (OSRAM)
JP (1) JP4705956B2 (OSRAM)
KR (2) KR101350420B1 (OSRAM)
CN (1) CN101068793B (OSRAM)
AR (2) AR052034A1 (OSRAM)
AT (2) ATE534645T1 (OSRAM)
AU (1) AU2005311671B8 (OSRAM)
BR (1) BRPI0518760A8 (OSRAM)
CA (1) CA2588398C (OSRAM)
CR (1) CR9146A (OSRAM)
CY (1) CY1112859T1 (OSRAM)
DK (1) DK1819700T3 (OSRAM)
EA (1) EA012418B1 (OSRAM)
ES (2) ES2375788T3 (OSRAM)
GE (1) GEP20105086B (OSRAM)
HR (1) HRP20120066T1 (OSRAM)
IL (1) IL183614A (OSRAM)
MA (1) MA29120B1 (OSRAM)
ME (1) ME01985B (OSRAM)
MX (1) MX2007006639A (OSRAM)
MY (1) MY144320A (OSRAM)
NI (1) NI200700138A (OSRAM)
NO (1) NO338784B1 (OSRAM)
NZ (1) NZ555376A (OSRAM)
PE (1) PE20061148A1 (OSRAM)
PL (1) PL1819700T3 (OSRAM)
PT (1) PT1819700E (OSRAM)
RS (1) RS52197B (OSRAM)
SI (1) SI1819700T1 (OSRAM)
TN (1) TNSN07215A1 (OSRAM)
TW (1) TWI344463B (OSRAM)
UA (1) UA87884C2 (OSRAM)
WO (2) WO2006060712A2 (OSRAM)
ZA (1) ZA200704130B (OSRAM)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1725528B1 (en) 2004-03-11 2013-05-29 4Sc Ag Sulphonylpyrroles as hdac inhibitors
TR201907729T4 (tr) * 2004-12-03 2019-06-21 Merck Sharp & Dohme Bir anti-çekirdekleştirici ajan içeren farmasötik bileşim.
US8852632B2 (en) * 2004-12-03 2014-10-07 Merck Sharp & Dohme Corp. Pharmaceutical formulation containing a release rate controlling composition
US20070259894A1 (en) * 2004-12-03 2007-11-08 Kelem Kassahun Use of Atazanavir for Improving the Pharmacokinetics of Drugs Metabolized by Ugt1a1
WO2007106768A2 (en) * 2006-03-14 2007-09-20 Merck & Co., Inc. Processes and apparatuses for the production of crystalline organic microparticle compositions by micro-milling and crystallization on micro-seed and their use
AU2007275805A1 (en) 2006-07-19 2008-01-24 University Of Georgia Research Foundation, Inc. Pyridinone diketo acids: Inhibitors of HIV replication in combination therapy
US7687509B2 (en) * 2007-07-09 2010-03-30 Concert Pharmaceuticals Inc. Pyrimidinecarboxamide derivatives
CN103254138A (zh) * 2008-01-08 2013-08-21 默沙东公司 用于制备n-取代的羟基嘧啶酮羧酰胺类化合物的方法
US8742105B2 (en) 2009-06-02 2014-06-03 Hetero Research Foundation Polymorphs of raltegravir potassium
WO2011024192A2 (en) 2009-07-27 2011-03-03 Matrix Laboratories Ltd Novel polymorphs of raltegravir
HUE057248T2 (hu) * 2009-10-26 2022-04-28 Merck Sharp & Dohme Integráz inhibitort tartalmazó szilárd gyógyszerészeti kompozíciók
DE102009056636A1 (de) 2009-12-02 2011-06-09 Ratiopharm Gmbh Raltegravir-Polymorphe
EA201270651A1 (ru) * 2009-12-07 2013-01-30 Юниверсити Оф Джорджия Рисерч Фаундейшн, Инк. Карбоксамиды пиридинон гидроксициклопентила: ингибиторы вич интегразы и области терапевтического применения
ES2362598B1 (es) * 2009-12-17 2012-06-13 Consejo Superior De Investigaciones Científicas (Csic) Uso del raltegravir y derivados para la elaboración de medicamentos destinados al tratamiento de infecciones por herpesvirus.
CA2794952C (en) * 2010-04-01 2018-05-15 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
EP2545048B1 (en) * 2010-04-01 2014-10-08 Teva Pharmaceutical Industries Ltd. Raltegravir salts and crystalline forms thereof
EP2575465A4 (en) * 2010-05-25 2013-11-20 Hetero Research Foundation Raltegravir SALTS
US9107922B2 (en) 2010-07-16 2015-08-18 Concert Pharmaceuticals, Inc. Pyrimidinecarboxamide derivatives
CN101914067B (zh) * 2010-08-26 2012-07-11 陈岱岭 N-甲基嘧啶酮的合成方法
JO3209B1 (ar) * 2010-11-05 2018-03-08 H Lundbeck As طريقة لتصنيع نالتريكسون
WO2012103105A1 (en) 2011-01-24 2012-08-02 Assia Chemical Industries Ltd. Processes for preparing raltegravir and intermediates in the processes
WO2012106534A2 (en) * 2011-02-02 2012-08-09 The Regents Of The University Of California Hiv integrase inhibitors
AU2012241050B2 (en) 2011-04-06 2016-05-19 Lupin Limited Novel salts of raltegravir
EP2699094A4 (en) * 2011-04-22 2014-12-17 Merck Sharp & Dohme TASTE-MASKED FORMULATIONS BY RALTEGRAVIR
US9968607B2 (en) 2011-04-25 2018-05-15 Hetero Research Foundation Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof
EP2522665A1 (en) * 2011-05-03 2012-11-14 Sandoz Ag Crystalline sodium salt of an HIV integrase inhibitor
EP2529741B1 (en) 2011-06-01 2014-02-12 Ratiopharm GmbH Composition and Tablet Comprising Raltegravir
WO2013037731A1 (de) 2011-09-16 2013-03-21 Hexal Ag Neue polymorphe form von raltegravir-kalium
CN103130787B (zh) * 2011-11-24 2015-06-10 南开大学 嘧啶酮酰胺类化合物及其制备方法、抗hiv活性和抗tmv活性
CN103130788B (zh) * 2011-11-24 2015-09-02 南开大学 嘧啶酰胺类化合物及其制备方法、抗hiv活性和抗tmv活性
WO2013098854A2 (en) * 2011-12-26 2013-07-04 Emcure Pharmaceuticals Limited Synthesis of raltegravir
JP2015504913A (ja) 2012-01-25 2015-02-16 ルピン・リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ 安定な非晶質のラルテグラビルカリウムプレミックス、及び、その調製方法
WO2014064711A2 (en) * 2012-10-22 2014-05-01 Hetero Research Foundation Methods of administering raltegravir and raltegravir compositions
EP2818470A1 (en) 2013-06-27 2014-12-31 Basf Se Cocrystals of raltegravir potassium
EP3022209B1 (en) * 2013-07-17 2018-03-07 ratiopharm GmbH Dolutegravir potassium salt
EP3102565B1 (en) 2014-02-03 2019-01-02 Mylan Laboratories Ltd. Processes for the preparation of intermediates of raltegravir
US10391178B2 (en) 2014-03-21 2019-08-27 Mylan Laboratories Limited Premix of crystalline raltegravir potassium salt and a process for the preparation thereof
US10257840B2 (en) 2014-10-22 2019-04-09 Telefonaktiebolaget Lm Ericsson (Publ) Operation of wireless local area network in the presence of periodic interference
US10259778B2 (en) 2014-11-10 2019-04-16 Aurobindo Pharma Ltd Process for the preparation of raltegravir
EP3472134B1 (en) 2016-06-21 2021-10-20 Pharmathen S.A. Process for preparing compounds useful as intermediates for the preparation of raltegravir
US10752618B2 (en) 2016-09-15 2020-08-25 Lupin Limited Process for the preparation of pure and stable crystalline Raltegravir potassium form 3
CN108610338A (zh) * 2016-12-12 2018-10-02 天津国际生物医药联合研究院 一种嘧啶酮酰胺类化合物的制备方法
WO2019096773A1 (en) 2017-11-14 2019-05-23 Cambrex Profarmaco Milano S.R.L. Process for the preparation of raltegravir
WO2019236395A1 (en) * 2018-06-06 2019-12-12 Merck Sharp & Dohme Corp. Formulations of raltegravir
GB201907305D0 (en) * 2019-05-23 2019-07-10 Douglas Pharmaceuticals Ltd Treatment of conditions
EP4093380A1 (en) 2020-01-23 2022-11-30 Lupin Limited Pharmaceutical compositions of raltegravir

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH624391A5 (OSRAM) * 1976-12-14 1981-07-31 Ciba Geigy Ag
US5717097A (en) 1991-11-08 1998-02-10 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
IL121789A (en) * 1996-10-03 2001-06-14 Rohm & Haas A medicinal product for inhibiting mammalian cell tumors
RU2225860C2 (ru) 1998-12-25 2004-03-20 Шионоги & Ко., Лтд. Ароматические гетероциклические соединения, обладающие активностью в отношении вич-интегразы
IT1318424B1 (it) 2000-03-24 2003-08-25 Unihart Corp Composti con attivita' anti-hiv.
IL155089A0 (en) 2000-10-12 2003-10-31 Merck & Co Inc Aza and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
GB0028483D0 (en) 2000-11-22 2001-01-10 Hoffmann La Roche Hydroxyethylamine HIV protease inhibitors
DK1441735T3 (da) 2001-10-26 2006-06-12 Angeletti P Ist Richerche Bio N-substituerede hydroxypyrimidinon-carboxamid-inhibitorer af HIV-integrase
US7354932B2 (en) 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
CN1596255A (zh) 2001-12-21 2005-03-16 阿诺麦德股份有限公司 具有强效的与趋化因子受体结合的杂环化合物
SI1564210T1 (sl) 2002-11-20 2010-01-29 Japan Tobacco Inc 4-oksokinolinske spojine in njihova uporaba kot inhibitorji HIV integraze
KR20050087865A (ko) 2002-12-27 2005-08-31 이스티투토 디 리세르쉐 디 비올로지아 몰레콜라레 피. 안젤레티에스.피.에이. ＨＩＶ 인테그라제 억제제로서 유용한테트라하이드로-4Ｈ-피리도[1,2-ａ]피리미딘 및 관련화합물
TW200423930A (en) 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
US8852632B2 (en) * 2004-12-03 2014-10-07 Merck Sharp & Dohme Corp. Pharmaceutical formulation containing a release rate controlling composition
TR201907729T4 (tr) 2004-12-03 2019-06-21 Merck Sharp & Dohme Bir anti-çekirdekleştirici ajan içeren farmasötik bileşim.
US20070259894A1 (en) 2004-12-03 2007-11-08 Kelem Kassahun Use of Atazanavir for Improving the Pharmacokinetics of Drugs Metabolized by Ugt1a1

Also Published As

Publication number Publication date
BRPI0518760A8 (pt) 2017-12-12
ATE518844T1 (de) 2011-08-15
MY144320A (en) 2011-08-29
CN101068793A (zh) 2007-11-07
NO20073404L (no) 2007-07-02
EA200701204A1 (ru) 2007-12-28
NO338784B1 (no) 2016-10-17
HK1115011A1 (en) 2008-11-14
IL183614A (en) 2012-03-29
KR20130122031A (ko) 2013-11-06
PL1819700T3 (pl) 2012-04-30
EP1819700B1 (en) 2011-11-23
MX2007006639A (es) 2007-06-19
GEP20105086B (en) 2010-10-11
TNSN07215A1 (en) 2008-11-21
JP2008521933A (ja) 2008-06-26
CN101068793B (zh) 2011-05-25
CA2588398C (en) 2011-07-12
WO2006060712A3 (en) 2006-09-21
KR20070089990A (ko) 2007-09-04
TWI344463B (en) 2011-07-01
ZA200704130B (en) 2008-08-27
AR052034A1 (es) 2007-02-28
TW200631944A (en) 2006-09-16
PE20061148A1 (es) 2006-11-09
JP4705956B2 (ja) 2011-06-22
CA2588398A1 (en) 2006-06-08
RS52197B (sr) 2012-10-31
US20060122205A1 (en) 2006-06-08
ES2370136T3 (es) 2011-12-13
MA29120B1 (fr) 2007-12-03
IL183614A0 (en) 2007-09-20
UA87884C2 (uk) 2009-08-25
US8357798B2 (en) 2013-01-22
NI200700138A (es) 2008-05-13
PT1819700E (pt) 2012-02-01
AR101429A2 (es) 2016-12-21
AU2005311671B2 (en) 2011-01-27
WO2006060730A2 (en) 2006-06-08
ES2375788T3 (es) 2012-03-06
DK1819700T3 (da) 2012-03-19
EP1819683B1 (en) 2011-08-03
CR9146A (es) 2007-10-04
EP1819683A2 (en) 2007-08-22
NZ555376A (en) 2009-11-27
SI1819700T1 (sl) 2012-07-31
AU2005311671B8 (en) 2011-02-10
AU2005311671A1 (en) 2006-06-08
WO2006060730A3 (en) 2006-08-17
EA012418B1 (ru) 2009-10-30
BRPI0518760A2 (pt) 2008-12-09
US20100249410A1 (en) 2010-09-30
US7754731B2 (en) 2010-07-13
WO2006060712A9 (en) 2006-07-27
WO2006060712A2 (en) 2006-06-08
ME01985B (me) 2012-10-31
KR101350420B1 (ko) 2014-02-17
EP1819700A2 (en) 2007-08-22
ATE534645T1 (de) 2011-12-15
CY1112859T1 (el) 2016-04-13

Similar Documents

Publication Publication Date Title
HRP20120066T1 (hr) Kalijeva sol inhibitora hiv integraze
MX2022007842A (es) Derivados biciclicos sustituidos de piperidina utiles como activadores de celulas t.
RU2014110399A (ru) Кристаллические формы вгс протеазного ингибитора
MX2022007372A (es) Compuestos de heteroarilo sustituidos utiles como activadores de celulas t.
RU2014145544A (ru) Солевая форма ингибитора гистон-метилтрансферазы ezh2 человека
NZ742200A (en) Treatment of osteoarthritis
NZ604345A (en) Pyrazolo[1,5-a]pyrimidines as antiviral agents
RU2012146517A (ru) Соли ральтегравира и их кристаллические формы
HRP20140666T1 (hr) Kristalni oblici derivata 2-tiazolil-4-kinolinil-oksi, snažnog hcv-inhibitora
MY139399A (en) Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
TW200736258A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
UA129695C2 (uk) Спосіб отримання та кристалічні форми проміжного продукту в синтезі інгібітора mdm2
FI4003532T3 (fi) 7-kloori-2-(4-(3-metoksiatsetidin-1-yyli)sykloheksyyli)-2,4-dimetyyli-n-((6-metyyli-4-(metyylitio)-2-okso-1,2-dihydropyridin-3-yyli)metyyli)bentso[d][1,3]dioksoli-5-karboksamidin kiteisiä muotoja
RU2012140021A (ru) КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНИЛ)-5Н-ПИРИМИДО[5,4-d][2]БЕНЗАЗЕПИН-2-ИЛ]АМИНО}-2-МЕТОКСИБЕНЗОАТА НАТРИЯ
ZA200809820B (en) A novel crystalline form of lamivudine
MY204339A (en) Novel calcium salt polymorphs as anti-inflammatory, immunomodulatory and anti-proliferatory agents
JO2684B1 (en) Quinoline antibacterial derivatives
RU2012140431A (ru) Стабильная кристаллическая форма 2-этил-3,7-диметил-6-(4-(трифторметокси) фенокси) хинолин-4-илметилкарбоната, способ ее получения и агрохимическая композиция, содержащая данную кристаллическую форму
HRP20120700T1 (hr) SOLI SPOJEVA INHIBITORA HIV-a
MX384745B (es) Proceso para la preparación de compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidina-2,7-diona 3-sustituidos.
GB2605894A (en) 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-quinoline-3-carboxamide potassium salt
MX2011012068A (es) Nucleosidos 2'-fluoro arabino y su utilizaicon.
IL266097B (en) " a mono-orotate acid addition salt of (r)-5-((e)-2-pyrrolidin-3-ylvinyl)pyrimidine”
JO2725B1 (en) Quinoline antibacterial derivatives
WO2014014794A3 (en) Mineralocorticoid receptor antagonists